Earnings summaries and quarterly performance for TransMedics Group.
Executive leadership at TransMedics Group.
Waleed H. Hassanein, M.D.
Detailed
President and Chief Executive Officer
CEO
AR
Anil Ranganath
Detailed
Senior Vice President, General Counsel and Corporate Secretary
GH
Gerardo Hernandez
Detailed
Chief Financial Officer and Treasurer
NC
Nicholas Corcoran
Detailed
Senior Vice President of Supply Chain and Operations
TK
Tamer Khayal, M.D.
Detailed
Chief Commercial Officer
Board of directors at TransMedics Group.
Research analysts who have asked questions during TransMedics Group earnings calls.
DR
David Rescott
Baird
4 questions for TMDX
Also covers: HAE, INSP, IRTC +7 more
JJ
Joshua Jennings
TD Cowen
4 questions for TMDX
Also covers: ABT, ALUR, ATEC +20 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for TMDX
Also covers: ABT, AORT, ATRC +14 more
AG
Allen Gong
JPMorgan Chase & Co.
3 questions for TMDX
Also covers: ESTA, GKOS, INGN +2 more
Michael Matson
Needham & Company
3 questions for TMDX
Also covers: AORT, ATRC, CNMD +22 more
William Plovanic
Canaccord Genuity
3 questions for TMDX
Also covers: ATRC, CBLL, CVRX +9 more
Christopher Pasquale
Nephron Research
2 questions for TMDX
Also covers: ALC, AXGN, BSX +12 more
MO
Matthew O'Brien
Piper Sandler & Co.
2 questions for TMDX
Also covers: APYX, ATEC, ATRC +18 more
CG
Cecilia Gong
JPMorgan Chase & Co.
1 question for TMDX
Chris Pasquale
Nephron Research LLC
1 question for TMDX
Also covers: ALC, AXGN, BSX +7 more
Justin Lang
Morgan Stanley
1 question for TMDX
Also covers: CW, GOGO, IRDM +3 more
Matthew Mardula
William Blair
1 question for TMDX
Also covers: ASTH, HCSG, LFST +1 more
Mike Matson
Needham & Company, LLC
1 question for TMDX
Also covers: CNMD, ENOV, ESTA +16 more
RD
Ryan Daniels
William Blair & Company, L.L.C.
1 question for TMDX
Also covers: ACCD, AGL, ALHC +12 more
SM
Samantha Munoz
Piper Sandler Companies
1 question for TMDX
Also covers: ATEC, CVRX, PEN +1 more
XW
Xuesong Wang
Morgan Stanley
1 question for TMDX
Also covers: SONX
Zachary Day
Canaccord Genuity
1 question for TMDX
Also covers: ATRC
Recent press releases and 8-K filings for TMDX.
TransMedics Discusses Growth Strategy, Clinical Trials, and Financial Targets at J.P. Morgan Conference
TMDX
Product Launch
New Projects/Investments
Guidance Update
- TransMedics is advancing its Organ Care System (OCS) technology with the planned introduction of the OCS Kidney platform (Gen3 technology) by late 2026 or early 2027, and recently secured unconditional FDA approval for the OCS Lung de Novo trial on January 12, 2026.
- The company achieved high organ utilization rates through its National OCS Program (NOP) as of 2024 year-end: Liver 98%, Heart 97%, and Lung 96%, which are noted as the highest reported in the history of organ transplant.
- TransMedics outlined significant growth targets, aiming for 10,000 US transplants by 2028, 20,000 US transplants by 2030 (incorporating kidney), and 30,000 global transplants by 2032 through continued US expansion and new international markets like Italy.
- Financially, TransMedics targets a long-term gross margin of approximately 60% and an operating margin approaching 30% by 2028, supported by its scalable operating model and international growth initiatives.
3 days ago
TransMedics Outlines Growth Strategy and Financial Targets at J.P. Morgan Healthcare Conference
TMDX
Product Launch
New Projects/Investments
Guidance Update
- TransMedics (TMDX) announced ambitious growth targets, aiming for 10,000 U.S. transplants by 2028, 20,000 U.S. transplants by 2030, and 30,000 global transplants by 2032.
- The company is introducing its new OCS Kidney platform by the end of 2025 or beginning of 2026, and the OCS Lung DENOVO trial received unconditional FDA approval on January 12, 2026.
- TransMedics expects a long-term gross margin of around 60% and an operating margin approaching 30% by 2028.
- The National OCS Program (NOP) has driven significant increases in organ utilization, with rates of 98% for liver, 97% for heart, and 96% for lung as of 2024 year-end.
- International expansion is underway with the launch of the EU NOP model starting in Italy in 2026.
3 days ago
TransMedics Receives FDA Approval for OCS Lung de Novo Trial and Outlines Growth Targets
TMDX
Product Launch
Guidance Update
New Projects/Investments
- TransMedics announced that the OCS Lung de Novo trial received unconditional FDA approval on January 12, 2026, and the company plans to initiate the trial soon.
- The company is targeting 10,000 US transplants by 2028, 20,000 US transplants by 2030, and 30,000 global transplants by 2032, driven by expansion into new organs like the OCS Kidney and international markets.
- TransMedics reported high organ utilization rates with its OCS National OCS Program (NOP) as of 2024 year-end: liver 98%, heart 97%, and lung 96%.
- The company expects a long-term gross margin of around 60% and aims for an operating margin approaching 30% by 2028.
3 days ago
TransMedics Leases New Global Headquarters and Manufacturing Hub
TMDX
New Projects/Investments
- TransMedics Group has entered into a 16-year lease for a 498,000-square-foot facility at Assembly Innovation Park in Somerville, Massachusetts.
- This facility will serve as TransMedics' new global headquarters and manufacturing hub.
- The company also acquired an adjacent land parcel and a portion of the parking structure within the campus to support future growth.
4 days ago
TransMedics Group, Inc. Secures New Headquarters and Acquires Adjacent Properties
TMDX
New Projects/Investments
- TransMedics Group, Inc. (TMDX) entered into a lease agreement on January 8, 2026, for approximately 498,286 square feet of space at 188 Assembly Park Drive, Somerville, MA, which is expected to serve as its new principal executive offices and for research, development, manufacturing, and other uses starting on or before January 1, 2028.
- The lease has an initial term of 192 months (16 years) from the Rent Commencement Date (no later than February 1, 2028), with two consecutive options to extend for ten years each, and an additional option for a six-month extension.
- The initial annual base rent will be approximately $23.9 million, subject to a 2% annual increase for the first four years, and then a 3% annual increase thereafter. The company is also responsible for 100% of annual operating and tax expenses and a 3% Property Management Fee of the Base Rent.
- A security deposit of approximately $18 million was provided to the landlord in the form of a letter of credit.
- On the same date, the Company acquired two parcels adjacent to the leased premises in Somerville, Massachusetts, for a total purchase price of $30.0 million (two parcels at $15.0 million each).
4 days ago
TransMedics Details Organ Transplant Growth Strategy and 2028 Financial Targets
TMDX
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- TransMedics (TMDX) aims for 80%-90% adoption of OCS machine perfusion for liver transplants, up from the current 40%, citing significant survival differences and improved post-transplant complication rates. Major publications supporting this are expected in the first half of 2026.
- The company is highly confident in achieving 10,000 transplants by 2028. Clinical trials for heart have started enrollment, and lung trials are expected to begin in late 2025/early 2026, aiming to enable scheduled transplants for these organs.
- TransMedics plans to introduce kidney transplants in 2027, targeting a market of 23,000 kidneys transplanted annually and an additional 10,000 rejected kidneys. The OCS technology is expected to reduce complication rates and improve supply, which could significantly impact CMS costs.
- CFO Gerardo Hernandez stated the goal is to reach or approach a 30% operating margin by 2028, driven by continued growth and disciplined operating expense management.
- The company is developing a Gen3 OCS technology that is fully automated, with improved cost of goods and remote capabilities, designed to support 20,000-30,000 transplants for 2028 and beyond.
Dec 2, 2025, 2:30 PM
TransMedics and AtriCure Discuss Growth Strategies at Piper Sandler Conference
TMDX
New Projects/Investments
Guidance Update
Product Launch
- TransMedics (TMDX) is highly confident in achieving 10,000 transplants by 2028 and aims to reach an operating margin of 30% by 2028.
- TMDX has initiated enrollment for heart clinical trials and anticipates starting lung trials by early January.
- TMDX plans to expand into kidney transplants in 2027, targeting a market that includes 23,000 deceased kidney transplants and an additional 10,000 kidneys rejected annually in the US.
- AtriCure reported 18.5% growth in its clip business in Q3, attributing this acceleration to the FlexMini product, launched in Q4 last year, which is 60% smaller than competing products.
Dec 2, 2025, 2:30 PM
TransMedics Outlines Growth Strategy, New Organ Markets, and Profitability Targets
TMDX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- TransMedics (TMDX) is highly confident in achieving 10,000 transplants by 2028 and aims for an operating margin of 30% by 2028.
- The company is expanding into the kidney transplant market, which is projected to launch in 2027 and represents a potential volume 1.5 times the combined total of heart, lung, and liver transplants.
- Clinical trials for heart have commenced, and lung trials are anticipated to begin by early January 2026. Major publications detailing liver registry data are expected in the first half of 2026.
- Operational efficiencies are being pursued, including double-shifting pilots to enable 24/7 jet operation, with results expected in the first half of 2026.
Dec 2, 2025, 2:30 PM
TransMedics Group Inc. Reports Strong Q3 2025 Results and Updates Full-Year Guidance
TMDX
Earnings
Guidance Update
New Projects/Investments
- TransMedics Group Inc. reported Q3 2025 total revenue of $143.8 million, representing approximately 32.2% growth year over year, with an overall gross margin of approximately 59%. The company achieved net income of $24 million, a 477% year-over-year increase, and diluted earnings per share of $0.66 for the quarter.
- The company ended Q3 2025 with $466.2 million in cash, an increase of approximately $65.6 million from June 30, 2025, driven by strong operating cash generation.
- TransMedics narrowed its full-year 2025 revenue guidance to a range of $595 million to $605 million, which at the midpoint represents approximately 36% growth over full year 2024. It also expects to deliver at least 750 basis points of operating margin expansion for the full year 2025 compared to 2024.
- Strategic initiatives include the planned launch of its first ex-U.S. National OCS Program in Italy in the first half of 2026 and the expected initiation of patient enrollment for the Enhanced Heart and De Novo Lung clinical trials in Q4 2025.
- The company is also making progress on its OCS kidney program, with the design expected to be revealed in early 2026, and is in the final stages of lease negotiations for a new global headquarters in Somerville, Boston area, with an announcement expected in early January 2026.
Oct 29, 2025, 8:30 PM
TransMedics Reports Strong Q3 2025 Results and Updates Full-Year Guidance
TMDX
Earnings
Guidance Update
New Projects/Investments
- TransMedics Group Inc. reported Q3 2025 revenue of $143.8 million, representing 32.2% year-over-year growth, and an operating profit of $23.3 million, or 16% of total revenue. The company ended the quarter with over $466.2 million in cash, adding approximately $65.6 million to its balance sheet.
- The company narrowed its full-year 2025 revenue guidance to $595 million-$605 million, with the midpoint representing approximately 36% growth over 2024. It also expects to deliver at least 750 basis points of operating margin expansion for the full year 2025 compared to 2024.
- Patient enrollment for the next-gen OCS Enhanced Heart and De Novo Lung clinical trials is expected to commence in Q4 2025, with all IDE conditions for both trials anticipated to be satisfied by early next year.
- TransMedics plans to launch its first ex-U.S. National OCS Program in Italy in the first half of 2026.
Oct 29, 2025, 8:30 PM
Quarterly earnings call transcripts for TransMedics Group.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more